



Intercell names Reinhard Kandra Chief Financial Officer

Vienna, Austria, March 6, 2009 – Intercell AG (VSE: ICLL) today announced that Reinhard Kandra has been appointed as Chief Financial Officer (CFO). In his new role he will be responsible for the global Finance Function and Investor Relations of Intercell AG.

Reinhard Kandra is currently CFO of Intercell's US subsidiary (formerly Iomai Corporation), which was acquired in 2008. He joined Intercell in 2001 and has held various positions within Finance including Global Head of Investor Relations and Head of Finance and Controlling. Reinhard Kandra has made pivotal contributions to the successful integration of Intercell's acquisitions in Scotland and in the USA and has implemented all the strategic funding activities of the company. Before joining Intercell he worked for Deutsche Bank AG. He holds doctorate degrees in both law and finance.

The prior CFO, Werner Lanthaler, will be leaving the company with effect from March 6 to join Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) as Chief Executive Officer (CEO). Werner Lanthaler has completed a full hand-over of his responsibilities to Reinhard Kandra as would be expected given the long, successful working relationship between both executives and most friendly nature of the transition.

Werner Lanthaler contributed significantly to the success of Intercell for more than 8 years cumulating in the approval of Intercell's first marketed product. Werner Lanthaler has spearheaded a series of excellent strategic partnerships, as well as achieved sustainable profitability and a very solid financial situation without further funding needs for Intercell. He also made key contributions to private venture fund raisings in the early years of the company, the IPO in 2005, the strategic alliance with Novartis in 2007 and several transforming strategic initiatives including two major acquisitions.

"Werner's contributions were pivotal to making Intercell one of the most successful young biotech companies globally and we want to thank him for his outstanding work. We are glad that he will continue to be available as a strategic advisor to the company and wish him all the best for his future plans", stated Michel Gréco, Chairman of the Intercell Supervisory Board

"It has been a great experience for me and the Management Board and all employees of Intercell to build the company together with Werner. We understand and respect his decision and we would like to express our deep gratitude for his outstanding performance. We are very happy that Reinhard Kandra will now take over the role of the CFO. His experience and knowledge of all company processes make him highly qualified for the next growth phase of Intercell", stated Gerd Zettlmeissl, Chief Executive Officer of Intercell.

"It has always been a privilege to contribute towards making Intercell an outstanding player in the global vaccine industry, and I am convinced that the company is excellently positioned for its next successful growth steps. I want to thank my colleagues and especially our investors





and business partners for their strong support over the past 8 years, which made my time at Intercell a fantastic personal and professional experience”, stated Werner Lanthaler.

The Management Board of Intercell AG will consist of Gerd Zettlmeissl (Chief Executive Officer), Thomas Lingelbach (Chief Operating Officer) and Alexander von Gabain (Chief Scientific Officer) until further appointments will be made.

About Intercell AG

Intercell AG is a growing biotechnology company that designs and develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs. Intercell's vaccine to prevent Japanese Encephalitis is the company's first product on the market.

The Company's technology platforms include an antigen-discovery system, adjuvants and a novel patch-based delivery system. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck & Co., Inc., Wyeth, Sanofi Pasteur, Kyowa Hakko Kirin and the Statens Serum Institut.

The Company's development pipeline includes Phase II vaccine programs for *Pseudomonas* (in-house development) and *S. aureus*, which is being developed with Merck & Co. Inc. The Company's novel Travelers' Diarrhea vaccine patch will enter Phase III testing in 2009. Intercell is also in clinical trials of a vaccine enhancement patch with injected Pandemic Influenza vaccines (one shot plus patch). In addition, four other products focused on infectious diseases are in pre-clinical development.

Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information, please visit: www.intercell.com

Contact Intercell AG

Intercell AG

Lucia Malfent

Head of Corporate Communications

Campus Vienna Biocenter 3, A-1030 Vienna

P: +43-1-20620-1303

Mail to: LMalfent@intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.